Evidence map›Paper›PMID 39627772›Full record

ArticleJournal of neuroinflammation2024

Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns.

Luisa Knecht, Katrine Dalsbøl, Anja Hviid Simonsen, Falk Pilchner, Jean Alexander Ross, Kristian Winge, Lisette Salvesen, Sara Bech, Anne-Mette Hejl, Annemette Løkkegaard and 6 more

Abstract read
In one paragraph

Article in Journal of neuroinflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. The spleen-brain axis in Alzheimer's disease and related dementias: Integrating immune and metabolic regulation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  5. Review
  6. The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Luisa Knecht *Centre for Neuroscience and Stereology, Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 6B, Entrance 11B, 2. floor, Copenhagen, NV, DK-2400, Denmark.
Katrine Dalsbøl *Centre for Neuroscience and Stereology, Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 6B, Entrance 11B, 2. floor, Copenhagen, NV, DK-2400, Denmark.
Anja Hviid SimonsenDanish Dementia Research Centre, Copenhagen University Hospital - Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen Ø, DK-2100, Denmark.
Falk PilchnerChair of Geriatric Medicine, Center for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen, Hufelandstraße 55, DE-45147, Essen, Germany.
Jean Alexander RossChair of Geriatric Medicine, Center for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen, Hufelandstraße 55, DE-45147, Essen, Germany.
Kristian WingeOdense University Hospital, University of Southern Denmark, Copenhagen, Denmark.
Lisette SalvesenDepartment of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 7, Copenhagen, NV, DK-2400, Denmark.
Sara BechDepartment of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 7, Copenhagen, NV, DK-2400, Denmark.
Anne-Mette HejlDepartment of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 7, Copenhagen, NV, DK-2400, Denmark.
Annemette LøkkegaardDepartment of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 7, Copenhagen, NV, DK-2400, Denmark.
Steen G HasselbalchDanish Dementia Research Centre, Copenhagen University Hospital - Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen Ø, DK-2100, Denmark.
Richard DodelChair of Geriatric Medicine, Center for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen, Hufelandstraße 55, DE-45147, Essen, Germany.
Susana AznarCentre for Neuroscience and Stereology, Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 6B, Entrance 11B, 2. floor, Copenhagen, NV, DK-2400, Denmark.
Gunhild WaldemarDanish Dementia Research Centre, Copenhagen University Hospital - Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen Ø, DK-2100, Denmark.
Tomasz BrudekCentre for Neuroscience and Stereology, Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 6B, Entrance 11B, 2. floor, Copenhagen, NV, DK-2400, Denmark. Tomasz.Brudek@regionh.dk.
Jonas FolkeCentre for Neuroscience and Stereology, Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 6B, Entrance 11B, 2. floor, Copenhagen, NV, DK-2400, Denmark. Jonas.folke@regionh.dk.

Funding

Danmarks Frie Forskningsfond 0129-00015BParkinsonforeningen A457
6 · The paper itself

Abstract

backgroundAlzheimer’s disease (AD) and Parkinson’s disease (PD) are leading neurodegenerative disorders marked by protein aggregation, with AD featuring amyloid-beta (Aβ) and tau proteins, and PD alpha-synuclein (αSyn). Dementia with Lewy bodies (DLB) often presents with a mix of these pathologies. This study explores naturally occurring autoantibodies (nAbs), including Immunoglobulin (Ig)G, IgM, and IgA, which target αSyn, Aβ and tau to maintain homeostasis and were previously found altered in AD and PD patients, among others. MAIN TEXT: We extended this investigation across AD, PD and DLB patients investigating both the affinities of IgGs and levels of IgGs, IgMs and IgAs towards αSyn, Aβ and tau utilizing chemiluminescence assays. We confirmed that AD and PD patients exhibited lower levels of high-affinity anti-Aβ and anti-αSyn IgGs, respectively, than healthy controls. AD patients also showed diminished levels of high-affinity anti-αSyn IgGs, while anti-tau IgG affinities did not differ significantly across groups. However, DLB patients exhibited increased anti-αSyn IgG but decreased anti-αSyn IgM levels compared to controls and PD patients, with AD patients showing a similar pattern. Interestingly, AD patients had higher anti-Aβ IgG but lower anti-Aβ IgA levels than DLB patients. DLB patients had reduced anti-Aβ IgM levels compared to controls, and anti-tau IgG levels were lower in AD than PD patients, who had reduced anti-tau IgM levels compared to controls. AD patients uniquely showed higher anti-tau IgA levels. Significant correlations were observed between clinical measures and nAbs, with negative correlations between anti-αSyn IgG affinity and levels in DLB patients and a positive correlation with anti-αSyn IgA levels in PD patients. Disease-specific changes in nAb levels and affinity correlations were identified, highlighting altered immune responses.

conclusionThis study reveals distinctive nAb profiles in AD, DLB, and PD, pinpointing specific immune deficiencies against pathological proteins. These insights into the autoreactive immune system’s role in neurodegeneration suggest nAbs as potential markers for vulnerability to protein aggregation, offering new avenues for understanding and possibly diagnosing these conditions.

Indexed as

Alpha-synucleinAlzheimer’s diseaseAmyloid-betaDementia with lewy bodiesNaturally occurring autoantibodiesParkinson’s diseaseTau

Identifiers

PMID39627772
PMCPMC11613470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.